Si necesitas ayuda traduciendo este mensaje, por favor escribe a dhcfp@dhcfp.nv.gov, o llame (702) 668-4200 o (775) 687-1900
We will make reasonable accommodations for members of the public with a disability.
Please notify Nevada Medicaid as soon as possible to dhcfp@dhcfp.nv.gov.

Notice of Meeting to Solicit Public Comments and Intent to ActUpon Amendments to the Medicaid Services Manual (MSM)

Public Hearing April 29, 2025
Summary

Date and Time of Meeting:	April 29, 2025, at 10:07 AM
Name of Organization:	State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)
Place of Meeting:	Division of Health Care Financing and Policy 1919 College Parkway, Suite #120 Carson City, Nevada 89706

Teleconference and/or Microsoft Teams Attendees
(Note: This List May Not Include All Participants, Just Those Who Identified Themselves)

Kimberly Smalley, DHCFP
Casey Angres, DHCFP
Lauren M. Driscoll, Deputy Attorney General (DAG)
Theresa Carsten, DHCFP
Joleen Walker, DHCFP
Kaelyne Day, DHCFP
Amber Cronn, DHCFP
Casey Walker
Abraham Meza, DHCFP
JC Flowers, Nevada Health Centers
Joy Thomas, Anthem
Erica McAllister, DHCFP
Amy Levin, Anthem
Lindsey Bondiek, DHCFP
Deidre Manley, DHCFP
Regina C. De Rosa, Anthem
Deborah Jordan, DHCFP
Catherine Vairo, DHCFP
Dominic Gaon, Anthem
De Yates
Todd Rich, DHCFP
Rianna White, Fidelis-Rx
Nahayvee Flores-Rosiles, DHCFP
Antonio Brown, DHCFP
Monica Schiffer, DHCFP
Nhobelyn Kho, DHCFP
Lisa Glick, Fidelis-RX
Andre Cisne, Silver Summit Health Plan (SSHP)
Madeline Dunn, Carelon
Shadi A. Ahmed, Carelon
Christina Cobeo, DHCFP
Marilyn Juarez, Anthem
Eric Alonzo, Fidelis RX
David Gross, Pfizer
Frederick Gibison, Mercer
Ellen Flowers, DHCFP
Sarah Dearborn, DHCFP
Malinda Southard, DHCFP
Melody Hall-Ramirez, DHCFP
Jonathan Figueroa, DHCFP
Jennifer Krupp, DHCFP
Angela Stewart, Elevance Health
Jason Yates

Introduction:

Kimberly Smalley, Hearings Chief, DHCFP, opened the Public Hearing introducing herself, Theresa Carsten, Deputy Administrator, DHCFP, and Lauren M. Driscoll, DAG.

Kimberly Smalley – The notice for this public hearing was published on March 27, 2025, in accordance with Nevada Revised Statute (NRS) 422.2369.

1. **Public Comments:** There were none.

2. **Discussion and Proposed Adoption of Changes to MSM Addendum**

Subject: MSM Addendum – Section M, Page 3 and Addendum, Section B, Page 1

Nahayvee Flores-Rosiles, Tribal and Community Liaison in the Community and Provider Engagement Unit, DHCFP, presented updates to rename the Medical Care Advisory Committee (MCAC) to the Medicaid Advisory Committee (MAC) as well as the addition of the Beneficiary Advisory Council (BAC). Definitions were added and revised for both advisory groups in accordance with NRS 42 CFR 431.12 where the MAC and BAC were required for the state Medicaid agencies to implement and support. The definition states the purpose of the advisory groups is to advise on matters to the State Medicaid Director related to policy development and to the effective administration of the Medicaid program. It is also specified in the BAC definition that the advisory group is comprised of individuals with Medicaid-lived experience.

The policy updates that are being proposed do not negatively affect any Medicaid provider types (PT).

The effective date is May 1, 2025, pending Centers for Medicare and Medicaid Services (CMS) approval of the State Plan Amendment (SPA).

Public Comments: There were none.

Theresa Carsten approved the changes pending spelling and grammar changes.

Kimberly Smalley – Closed the Public Hearing for proposed adoption and changes to MSM Addendum – Section M, Page 3 and Addendum, Section B, Page 1.

3. **Discussion and Proposed Adoption and Changes to MSM Chapter 1200**

Subject: MSM Chapter 1200 – Prescribed Drugs

Antonio Brown, Chief of Pharmacy Services and Durable Medical Equipment (DME), DHCFP, presented the proposed revisions to Medicaid Services Manual (MSM) Chapter 1200 – Prescribed Drugs, to incorporate recommendations approved at the Drug Utilization Review (DUR) Board meeting.

Brown advised that the last reviewed DUR Board date on chapter changes was listed as March 20, but the correct date is January 16, 2025.

Brown outlined the proposed changes beginning with Immunomodulator Drugs where the section was revised to remove all drug names from the criteria. In Antiemetics, the hierarchy for the section has been updated. Abraxane®, paclitaxel albumin bound, dosage limits and duration of authorization have been updated. Anti-PD-1 Monoclonal Antibodies universal criteria for Tecentriq® has been updated to include additional therapies that could not have been received while using Tecentriq® therapy. The universal criteria for Darzalex® have been updated including dosage limits and duration of authorization. Under Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1), clinical criteria for Jemperli® have been updated to clarify eligibility criteria for endometrial carcinoma by adding advanced or recurrent disease as qualifying conditions. Revisions were made to Mismatch Repair Deficient (dMMR) Microsatellite Instability - High (MSI-H) and Polymerase Epsilon/Delta (POLE/POLD1) mutation cancer criteria to reflect use in unresectable or medically inoperable cases. A section was added for the indication of anal carcinoma and dosage limits and duration of authorization have been updated. Under Aranesp®, clinical criteria have been updated with current clinical guideline information, dosage limits, and duration of authorization. Under Pemetrexed, Alimta®; Pemfexy™, clinical criteria have been updated to include criteria used as a single agent or in combination with other agents. Additionally, dosage limits and duration of authorization have been updated. Under human epidermal growth factor receptor 2 (HER2) Inhibitors, clinical criteria for Herceptin®; Ogivri®; Kanjinti™; Trazimera™; Herzuma®; Ontruzant® have been updated to require a negative pregnancy test prior to initiating treatment. Additionally, clinical criteria for Gastric, Esophageal, and Esophagogastric Junction Cancers have been updated. Dosage limits and duration of authorization have also been updated. Rituxan®, Truxima®, Ruxience™, Riabni™, the clinical criteria have been updated to expand indications for adult B-cell lymphomas, including plasmablastic lymphoma and unresectable unicentric disease, and clarified first-line use for Human Immunodeficiency Virus (HIV)-related B-cell lymphoma. Castleman Disease now includes use as first-line therapy and progressive disease. Hairy Cell Leukemia criteria were revised to allow treatment for relapses occurring two or more years after initial therapy. Updates also included for the addition of systemic corticosteroids for Graft-Versus-Host Disease, removal of specific drugs from immunotherapy toxicity management, and changes to dosage limits, recertification, and prior authorization guidelines.

Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity.

Theresa Carsten approved the changes pending spelling and grammar changes.

Kimberly Smalley – Closed the Public Hearing for proposed adoption and changes to MSM Chapter 1200 – Prescribed Drugs.

4. Adjournment

There were no further comments, and Kimberly Smalley closed the Public Hearing at 10:17 AM.

A video version of this meeting is available through the DHCFP Compliance office. For more detailed information on any of the handouts, submittals, testimony and or comments please contact Jenifer Graham at** documentcontrol@dhcfp.nv.gov **with any questions.